产品
编 号：F599838
分子式：C24H24N4
分子量：368.47
分子式：C24H24N4
分子量：368.47
产品类型
规格
价格
是否有货
结构图
CAS No: 80259-18-3
产品详情
生物活性：
JP1302 is a potent, selective, high affinity antagonist of the α2C-adrenoceptor, with a Kb of 16 nM and a Ki of 28 nM for the human α2C-receptor. JP1302 shows antidepressant and antipsychotic-like effects. JP1302 can be used for neuropsychiatric disorders and renal dysfunction research.
体内研究：
JP1302 (1-10 μmol/kg) decreases immobility time in the FST to a level similar to that seen with 10-30?μmol/kg of the antidepressant Desipramine (HY-B1272A).JP1302 (5 μmol/kg, once) is capable of complete reversal of the impairment in PPI induced in Sprague-Dawley rats by the psychotomimetic NMDA receptor antagonist, phencyclidine and similar results are found in Wistar rats.JP1302 (3 mg/kg, IV, once) significantly ameliorates renal dysfunction.Animal Model:Male Sprague Dawley rats (8 weeks old)
Dosage:3 mg/kg
Administration:IV, pre-treatment: administered 5 min before the induction of ischemia, post-treatment: injected 45 min after the initiation of reperfusion
Result:Significantly ameliorated renal dysfunction in the rats at 24 h after reperfusion. post-ischemic administration of JP-1302 significantly ameliorated renal dysfunction, histological damage and reduced apoptotic cells and pro-inflammatory cytokine mRNA expression.
体外研究：
JP1302 shows about 100-fold higher affinity than for α2A or α2B.
JP1302 is a potent, selective, high affinity antagonist of the α2C-adrenoceptor, with a Kb of 16 nM and a Ki of 28 nM for the human α2C-receptor. JP1302 shows antidepressant and antipsychotic-like effects. JP1302 can be used for neuropsychiatric disorders and renal dysfunction research.
体内研究：
JP1302 (1-10 μmol/kg) decreases immobility time in the FST to a level similar to that seen with 10-30?μmol/kg of the antidepressant Desipramine (HY-B1272A).JP1302 (5 μmol/kg, once) is capable of complete reversal of the impairment in PPI induced in Sprague-Dawley rats by the psychotomimetic NMDA receptor antagonist, phencyclidine and similar results are found in Wistar rats.JP1302 (3 mg/kg, IV, once) significantly ameliorates renal dysfunction.Animal Model:Male Sprague Dawley rats (8 weeks old)
Dosage:3 mg/kg
Administration:IV, pre-treatment: administered 5 min before the induction of ischemia, post-treatment: injected 45 min after the initiation of reperfusion
Result:Significantly ameliorated renal dysfunction in the rats at 24 h after reperfusion. post-ischemic administration of JP-1302 significantly ameliorated renal dysfunction, histological damage and reduced apoptotic cells and pro-inflammatory cytokine mRNA expression.
体外研究：
JP1302 shows about 100-fold higher affinity than for α2A or α2B.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备